scholarly journals 1203Predictors of treatment and survival in hepatocellular carcinoma patients: A Bayesian parametric survival analysis

2021 ◽  
Vol 50 (Supplement_1) ◽  
Author(s):  
Belaynew Taye ◽  
Paul Clark ◽  
Gunter Hartel ◽  
Elizabeth Powell ◽  
Patricia Valery

Abstract Background Culturally and linguistically diverse communities face several challenges to receiving screening and curative treatment of hepatocellular carcinoma (HCC). We reported the predictors of receipt of treatment and survival in a cohort of patients diagnosed with HCC in Southeast Queensland. Methods Data from 1651 HCC patients (147 migrants) followed between January 1, 2007, and December 31, 2016 were analyzed using chi-square statistic to test for the association between socio-economic variables and receipt of treatment. Bayesian Weibull Accelerated Failure Time regression was used to identify predictors of time to death, and we reported time ratios. Results Receipt of surgical resection for HCC was associated with non-metropolitan residence (P=0.02), non-English language (P<0.001), country of origin (P<0.001), and hepatitis B virus etiology (P<0.001). The median survival time after HCC diagnosis was 9.0 months (interquartile range 2.0‒24.0). The strongest predictors of survival were undifferentiated tumor at presentation (time ratio (TR)=0.30, 95% credible interval (CrI) 0.23‒0.39), age ≥70 years (TR = 0.42, 95%CrI 0.34‒0.53), living in a remote area (TR = 0.67, 95%CrI 0.55‒0.80), and presence of ≥ 1 comorbidity (TR = 0.69 95%CrI 0.54‒0.90). Conclusions Improving access to HCC surveillance and uptake of timely curative treatment for persons living in remote areas and having socioeconomic disadvantage may help patients present to clinic with early stage tumor and provide better survival. Key messages Remoteness of residence is associated with late presentation, low rate of receipt of treatment and predicts survival of patients with HCC.

2017 ◽  
Vol 152 (5) ◽  
pp. S1197
Author(s):  
Chiranjeevi Gadiparthi ◽  
Rosann Cholankeril ◽  
Eddie L. Copelin ◽  
Mairin Joseph-Talreja ◽  
Muhammad Ali Khan ◽  
...  

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 193-193
Author(s):  
Ahmed Abdelhakeem ◽  
Ahmed Omar Kaseb ◽  
Rikita Hatia ◽  
Reham Abdel-Wahab ◽  
Hesham M. Amin ◽  
...  

193 Background: Circulating insulin-like growth factor-1 (IGF-1) significantly declines in patients (pts) with cirrhosis and hepatocellular carcinoma (HCC), reflecting damaged hepatocytes. The bioavailability of IGF-1 is controlled by insulin-like growth factor binding proteins (IGFBPs), which bind IGF-1. IGFBPs transcription is cell specific, and are secreted mainly by the liver. Variations in circulating IGFBPs in HCC pts, especially those with non-cirrhotic HCC, has not been elucidated. We investigated the expression of these proteins in HCC with and without cirrhosis. Methods: Under Institutional Review Board approval, we measured plasma levels of seven IGFBPs in 489 cirrhotic HCC pts, 274 non-cirrhotic HCC pts, 75 pts with cirrhosis without HCC, and 200 healthy controls. Also, we assessed variations in IGFBPs plasma level between early and advanced stage HCC in the presence and absence of cirrhosis. Levels of circulating biomarkers were summarized by descriptive statistics, and both Chi-square and ANOVA tests were used to compare levels between groups. Results: IGFBPs levels varied significantly between groups (Table). Moreover, IGFBP-3 was lower in HCC pts than in healthy controls ( P ≤ 0.001), and IGFBP-1, -2, -4, and -7 were higher in HCC without cirrhosis than in healthy controls ( P = 0.001 for all). Additionally, in non-cirrhotic HCC pts, a similar pattern was observed in advanced Stage HCC compared with early stage HCC. Conclusions: Levels of circulating IGFBPs may be associated with risk of non-cirrhotic HCC and could be used as markers for underlying liver damage. [Table: see text]


Author(s):  
Seyda Gunduz ◽  
Gia Saini ◽  
Nicole Segaran ◽  
Sailen Naidu ◽  
Indravadan Patel ◽  
...  

AbstractHepatocellular carcinoma (HCC) is the fastest-growing cancer worldwide, causing significant morbidity and mortality. Surgical resection, ablation, or transplantation is the best treatment option for patients with HCC. However, only about one-fifth of patients are suitable for such primary curative treatments due to underlying liver disease or rapid extension of the tumor. Image-guided locoregional therapies may prove an important alternative in this scenario, particularly transarterial radioembolization (TARE) with yttrium-90 (Y-90). Based on many studies, TARE can be considered a curative treatment option for patients with early-stage HCC, a bridge to transplantation, and a method for downstaging tumors to give patients with unresectable HCC a chance to potentially receive a curative treatment. TARE can be also combined with other treatment modalities to provide a better quality of life in patients when compared with systemic therapy in patients with unresectable HCC. Here, we discuss the use of TARE in the approach to HCC patients who are in early, intermediate, or advanced stages.


2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Sun Ah Kim ◽  
Eun Ju Cho ◽  
Sungyoung Lee ◽  
Young Youn Cho ◽  
Boram Kim ◽  
...  

AbstractFibronectin, a matrix glycoprotein aberrantly expressed in various tumor cells, is a known candidate biomarker for the early diagnosis of hepatocellular carcinoma (HCC). In this study, we investigated whether serum fibronectin levels could predict tumor recurrence in patients with early-stage HCC after curative treatment. A total of 83 patients who showed complete response after initial curative treatment were included. The levels of serum fibronectin at baseline and 4–6 weeks after initial treatment were analyzed with regard to their associations with recurrence. Multivariate logistic regression analyses were performed to construct a prognostic nomogram. Baseline fibronectin levels were not significantly correlated with tumor size, number, stage, and serum α-fetoprotein levels. However, decrease in serum fibronectin levels after treatment was significantly associated with reduced HCC recurrence in multivariate logistic regression (odds ratio, 0.009; p < 0.001). Furthermore, a nomogram consisting of gender and changes in serum fibronectin showed a good discriminatory capability for the prediction of HCC recurrence with an area under the receiver-operating curve of 0.87. In conclusion, changes in serum fibronectin levels may be a surrogate indicator for assessment of treatment response in patients with early HCC after curative treatment.


2019 ◽  
Vol 42 (2) ◽  
pp. 433-442 ◽  
Author(s):  
Kelvin K.C. Ng ◽  
Tan-To Cheung ◽  
Tiffany C.L. Wong ◽  
James Y.Y. Fung ◽  
Jeff W.C. Dai ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document